Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 0.9 Normal Saline Clear all

Conditions: Advanced Cancers, Dyspnea
Interventions: Fentanyl, Placebo, Walking Tests, Questionnaires; Drug · Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Smallpox
Interventions: MVA Smallpox Vaccine, Placebo, Live vaccinia virus vaccine; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 38 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Genital Herpes Simplex Type 2
Interventions: Matrix-M2, GEN-003, Placebo; Biological · Drug
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 8
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more

Conditions: Prostate Cancer, Robotic Prostatectomy, Foley Catheter Discomfort
Interventions: Bupivacaine, Saline; Drug
Lead sponsor: Columbia University; Other
Eligibility: 40 Years to 80 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Posterior Vitreous Detachment
Interventions: Ultrasound examination; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 60 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Photosensitive Epilepsy
Interventions: Valproic Acid, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 15 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Chesterfield, Missouri • Nashville, Tennessee

Conditions: Obstetric Labour, Premature
Interventions: Retosiban IV infusion, Placebo IV infusion; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 45 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 33
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 29 more

Conditions: Bacteriuria, Spinal Cord Injuries, Asymptomatic Bacteriuria, Escherichia Coli
Interventions: Phage Therapy, Placebo; Drug · Other
Lead sponsor: Barbara Trautner; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: St Louis, Missouri • Houston, Texas

Conditions: Acute Ischemic Stroke
Interventions: Redasemtide, Placebo; Biological · Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 17
States / cities: Tucson, Arizona • Sarasota, Florida • Augusta, Georgia + 14 more

Conditions: Lymphoma,Non-Hodgkin
Interventions: Copanlisib (Aliqopa, BAY80-6946), Placebo, Rituximab; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 16
States / cities: West Covina, California • Ashland, Kentucky • Louisville, Kentucky + 10 more

Conditions: Rib Fractures
Interventions: Ropivacaine, Normal Saline Flush, 0.9% Injectable Solution; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Sepsis
Interventions: Ketamine, Normal Saline placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 21 Years to 100 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Covid19, Cytokine Storm, Mechanical Ventilation Complication
Interventions: Anakinra, 0.9% Saline; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Ascites Hepatic
Interventions: OsrHSA 20 mg/kg IV, OsrHSA 40 mg/kg IV, OsrHSA 80 mg/kg IV, OsrHSA 140 mg/kg IV, OsrHSA 200 mg/kg IV, Placebo; Drug · Other
Lead sponsor: Healthgen Biotechnology Corp.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cypress, California

Conditions: Acute Ischemic Stroke
Interventions: Intra-arterial Tenecteplase, Intra-arterial Saline; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Safety Issues, Tolerability, Pharmacokinetics, Pharmacodynamics
Interventions: AVR-48, Placebo; Drug
Lead sponsor: AyuVis Research, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Stroke
Interventions: human chorionic gonadotropin (hCG), then epoetin alfa (EPO), Saline Placebo; Drug
Lead sponsor: Stem Cell Therapeutics Corp.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Orange, California

Conditions: Atrial Fibrillation
Interventions: Bupivacaine, Saline; Drug · Other
Lead sponsor: Christopher Connors, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Portland, Maine

Conditions: Liver Transplant; Complications, Vasoplegia
Interventions: Angiotensin II, Saline; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Myelofibrosis
Interventions: APLIDIN (plitidepsin); Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Fosaprepitant; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Dengue Fever
Interventions: Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV), Placebo; Biological
Lead sponsor: Takeda; Industry
Eligibility: 13 Years to 63 Years
Enrollment: 365 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Huntsville, Alabama • Peoria, Illinois • Newton, Kansas + 5 more

Conditions: Healthy
Interventions: Ad26.Mos4.HIV, Clade C gp140 plus adjuvant, Clade C gp140/Mosaic gp140 plus adjuvant, Placebo, gp140 HIV Bivalent Vaccine; Biological · Other
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 11
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more

Conditions: Autonomic Nervous System Disorders, Pure Autonomic Failure, Shy-Drager Syndrome, Orthostatic Hypotension, Dysautonomic
Interventions: Angiotensin-(1-7), Saline; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Breakthrough Dyspnea Fentanyl Study in Cancer Patients

ACAM 3000 MVA at Harvard Medical School

Evaluating New Formulation of Therapeutic HSV-2 Vaccine

Dorsal Penile Block for Post-Robotic Prostatectomy Foley Discomfort

High-frequency-ultrasound Annular Arrays for Ophthalmic Imaging

Effect of Valproic Acid Concentration on Photic Response

A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor

Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria

A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

The Erector Spinae Plane Block and Its Effect on Respiratory Status and Pain Management in Rib Fracture Patients

Immunomodulatory Properties of Ketamine in Sepsis

Anakinra, COVID-19, Cytokine Storm

A Study of OsrHSA in Adult Healthy Male and Female Volunteers

Intra-Arterial Tenecteplase Following Endovascular Thrombectomy for Large Vessel Occlusion Stroke

Single Ascending Dose and Multiple Ascending Dose Study of AVR-48

Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

Study to Evaluate the Effectiveness of SGB in Preventing Post-op Atrial Fibrillation

Angiotensin II in Liver Transplantation

Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis

Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma

Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults

Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure